AUTHORS
Mahmood Aldapt, M.B.B.S., Hemant Murthy, MD2, Omer Jamy, MD3, Chenyu Lin, MD4, Anand Ashwin Patel, MD5, Breanna Chandler, M.D.6, Rory Shallis I, MD7, Kendall Diebold, CNP, MSN8, Alexander Coltoff, MD9, Aaron D Goldberg, MD, PhD10, Jan Philipp Bewersdorf, MD11, Kenneth Zabel12, Charles Foucar, MD13, Yasmin Abaza, MD14, Guru Subramanian Guru Murthy, MD15, Neil D Palmisiano, MD, MS16, Adam Duvall, MD, MPH17, Vamsi Kota, MD18, Shyam A Patel, MD, PhD19, Amer M. Zeidan, MD20, Ehab Atallah, MD21, Mark R. Litzow, MD22, Mohamed Kharfan-Dabaja, MD23, James Foran, FRCPC24, Talha Badar, MD25
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Mayo Clinic, Jacksonville, Florida, United States
3 University of Alabama at Birmingham, Birmingham, United States
4 Duke Blood Cancer Center, Durham, North Carolina, United States
5 University of Chicago, Chicago, Illinois, United States
6 University of Chicago, Chicago, Illinois, United States
7 Yale School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
8 University of Alabama at Birmingham, Birmingham, United States
9 MUSC, Charleston, South Carolina, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Yale School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
12 University of New Mexico, Albuquerque, New Mexico, United States
13 University of New Mexico, Albuquerque, New Mexico, United States
14 Northwestern Memorial Hospital, Chicago, Illinois, United States
15 MEDICAL COLLEGE OF WISCONSIN, Milwaukee, Wisconsin, United States
16 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
17 University of Chicago, Chicago, Illinois, United States
18 Augusta University, Augusta, Georgia, United States
19 UMass Chan Medical School, Worcester, Massachusetts, United States
20 Yale School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
21 MEDICAL COLLEGE OF WISCONSIN, Milwaukee, Wisconsin, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Jacksonville, Florida, United States
24 Mayo Clinic, Jacksonville, Florida, United States
25 Mayo Clinic, Jacksonville, Florida, United States
ABSTRACT
Background:
TP53-mutated myeloid neoplasms (TP53-MT MN) carry a median overall survival (OS) of only 6–9 months, despite advances in myeloid malignancy therapeutics. While TP53-MT dictates prognosis, the frequency and significance of concurrent targetable MT remain poorly characterized. There is a knowledge gap as to whether their presence segregates a subset with distinct biology and improved outcomes in a TP53-MT MN cohort.
Methods:
We conducted a multicenter observational study across 15 U.S. academic centers under the COMMAND consortium. We reviewed the electronic medical records of 700 patients (pts) with TP53-MT advanced MN (AML and myelodysplastic syndrome with increased blasts of >5%). Disease diagnoses were centrally reviewed and classified according to the 2022 International Consensus Classification. Pts were stratified as targetable co-MT positive (TCM+; n=67, 9.6%; ≥1 IDH1/IDH2/FLT3/NPM1 MT) or targetable co-MT negative (TCM−; n=633; all four genes documented wild-type [wt]).
Baseline characteristics were compared with Fisher's exact and Wilcoxon rank-sum tests. OS and RFS were estimated by Kaplan-Meier and compared by log-rank test; composite complete remission (CRc = CR+CRi) and overall response rate (ORR = CRc+MLFS+PR) were compared by Fisher's exact test. To adjust for confounding, 1:1 propensity score matching (PSM) was performed among pts with AML on sex, age, AML subtype (de novo vs secondary), TP53 allele status, complex karyotype (CK), and allogeneic hematopoietic cell transplantation (alloHCT), matching pts with TCM+ to nearest TCM− (caliper 0.2 SD logit).
Results:
Pts with TCM+ had comparable age (67 years [18-97] vs 68 years [24-90], p=0.98), sex, and TP53 variant allele frequency. Pts with TCM+ had higher rates of coexisting DNMT3A (30% vs 10%, p<0.001), TET2 (31% vs 11%, p<0.001), ASXL1 (31% vs 6%, p<0.001), RUNX1 (18% vs 5%, p=0.001), RAS (17% vs 8%, p=0.03), splicing factor (15% vs 6%, p=0.03), and BCOR (9% vs 3%, p=0.04) MT compared to TCM−, whereas TCM− was characterized by higher incidence of multi-hit (MH) TP53 (71.0% vs 44.0%, p<0.001), higher isolated TP53-MT (all screened co-MTs documented as wt; 43.8% vs 0%, p<0.0001) and higher CK (88.2% vs 50.0%, p<0.0001).
In the unmatched cohort, TCM+ had similar ORR (63.8% vs 55.7%, p=0.35) and higher CRc (53.2% vs 36.0%, p=0.026). RFS trended higher in TCM+ (median 9.1 vs 6.0 mo, p=0.14), and OS was superior (median 14.4 vs 6.1 mo, p=0.0001). The OS benefit persisted after PSM (49 pts in each group; 11.3 vs 4.4 mo, p=0.018). Similarly, among non-alloHCT pts TCM+ had superior OS in both the unmatched (11.3 vs 4.4 mo, p<0.0001) and PSM (6.0 vs 2.9 mo, p=0.011) cohorts.
Overall, induction therapy consisted of HMA+VEN (n=239, 34.1%), 7+3 (n=119, 17.0%), HMA alone or other low-intensity regimens (n=114, 16.3%), CPX-351 (n=76, 11.0%), treatment on clinical trial (n=58, 8.3%), best supportive care/hydroxyurea (n=52, 7.4%), or other intensive regimens (n=24, 3.4%); induction therapy was not documented for 18 pts (2.6%). AlloHCT rates were comparable in TCM+ and TCM− (16.4% vs 15.8%)
Among pts receiving HMA+VEN (n=239), TCM+ (n=17) had higher CRc (84.6% vs 53.4%, p=0.04), and longer OS compared to TCM- (median 17.4 vs 5.7 mo, p=0.021). In contrast, response to intensive chemotherapy (IC) (7+3 or CPX-351, n=195) was comparable between cohorts (CRc 31.6% vs 25.5%, p=0.59; median OS 14.4 vs 6.6 mo, p=0.075).
Seventeen of 67 (25%) pts with TCM+ received a targeted inhibitor during their treatment course (13 IDHi, 3 FLT3i, 1 menin inhibitor): 6 as first-line, 8 as salvage, and 3 as maintenance post-alloHCT. Among 5 evaluable first-line inhibitor recipients, 3 achieved CR. A two-fold numerical OS advantage favored inhibitor recipients (median 20.2 vs 10.0 mo, p=0.24).
Conclusion:
IDH1, IDH2, FLT3, and NPM1 co-MT identify a biologically distinct and relatively favorable subset of TP53-MT MN. TCM+ cohort has less MH TP53 and CK, together with a richer co-MT profile, suggesting less dependence on TP53 loss and chromosomal instability. Pts with TCM+ had superior OS independent of alloHCT and appeared to derive preferential benefit from HMA+VEN, whereas responses to IC were similar between cohorts.
Although limited by small numbers, the survival advantage among TCM+ cohort warrants further evaluation. These findings support systematic testing for TCM+, use of HMA+VEN-based therapy, prospective evaluation of targeted agent combinations, and timely alloHCT referrals.
DISCLOSURES
Mahmood Aldapt, M.B.B.S.: No relevant conflicts of interest to declare.